AstraZeneca – Ovarian Cancer

Access Program Information

This is an open-label, single-arm, international, multicenter Multiple Patient Expanded
Access Program (MPEAP). The program is designed to provide treatment access to olaparib
tablets for patients with platinum-sensitive relapsed high-grade epithelial ovarian,
fallopian tube or primary peritoneal cancer without other treatment options or eligible for
an olaparib clinical trials.

Rare Disease: